Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study

被引:6
|
作者
Park, Joo-Hyun [1 ]
Song, Yun-Mi [2 ]
Jung, Jin-Hyung [3 ]
Han, Kyungdo [4 ]
机构
[1] Korea Univ, Coll Med, Dept Family Med, Ansan Hosp, Ansan, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Dept Family Med, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea
[3] Catholic Univ, Dept Biostat, Coll Med, Seoul, South Korea
[4] Soongsil Univ, Dept Stat & Actuarial Sci, Seoul, South Korea
关键词
Fractures; Gastroesophageal reflux; Histamine-2 receptor antagonist; Osteoporosis; Proton pump inhibitor; BONE-MINERAL DENSITY; HIP FRACTURE; VITAMIN-B-12; OMEPRAZOLE; MEDICATIONS; ABSORPTION; SECRETION; INCREASE; HEALTH; DRUGS;
D O I
10.1016/j.bone.2020.115306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The influence of proton pump inhibitors (PPIs) on the risk of osteoporotic fractures remains to be elucidated, especially in the Asian population. This study evaluated the risk of osteoporotic fractures in elderly female Korean PPI users compared to histamine-2 receptor antagonist (H2RA) users, as well as the relationship between fractures and the duration, dose, and pattern of use of PPI. We screened a nationwide cohort of elderly Korean women who underwent bone mineral density measurements during their 66-year-old life-transition medical examination between 2009 and 2014. Study subjects included 8903 cases diagnosed with new osteoporotic fractures and 44,515 matched controls (1:5 ratio based on cohort entry date, follow-up duration, and baseline osteoporosis status) without fractures. They were followed up until 2015. Information on the exposure to PPI or H2RA, occurrence of fracture, and covariates were obtained from the Korean National Health Insurance Service data. Covariate-adjusted odds ratio (aOR) and 95% confidence interval (CI) were estimated using conditional logistic regression analysis. PPI use was associated with an increased risk of osteoporotic fractures (aOR: 1.13, 95% CI: 1.07, 1.18) compared with H2RA-only use. Increasing duration of PPI use was positively associated with the risk of osteoporotic fracture [aOR (95% CI) of long-term PPI use (>= 1 year): 1.3 (1.09, 1.56)]. Recent PPI use within the last year was associated with an increased risk of fracture (aOR: 1.31, 95% CI: 1.23, 1.38), whereas remote PPI use was not (aOR: 0.98, 95% CI: 0.92, 1.04). The risk of fracture did not increase with the increasing cumulative PPI dose. Compared with the use of H2RA alone, PPI use was associated with an increased risk of osteoporotic fractures in elderly Korean women, particularly among those who had used PPI within the last year or for more than one year.
引用
收藏
页数:9
相关论文
共 45 条
  • [1] Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies
    Tran, K. T.
    McMenamin, U. C.
    Hicks, B.
    Murchie, P.
    Thrift, A. P.
    Coleman, H. G.
    Iversen, L.
    Johnston, B. T.
    Lee, A. J.
    Cardwell, C. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (01) : 55 - 64
  • [2] A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate
    Lee, Joongyub
    Youn, KyungEun
    Choi, Nam-Kyong
    Lee, Jin-Ho
    Kang, DongYoon
    Song, Hong-Ji
    Park, Byung-Joo
    JOURNAL OF GASTROENTEROLOGY, 2013, 48 (09) : 1016 - 1022
  • [3] Proton-pump inhibitor use and hip fractures in men: a population-based case-control study
    Adams, Annette L.
    Black, Mary Helen
    Zhang, Jian L.
    Shi, Jiaxiao M.
    Jacobsen, Steven J.
    ANNALS OF EPIDEMIOLOGY, 2014, 24 (04) : 286 - 290
  • [4] Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
    Pouwels, S.
    Lalmohamed, A.
    Souverein, P.
    Cooper, C.
    Veldt, B. J.
    Leufkens, H. G.
    de Boer, A.
    van Staa, T.
    de Vries, F.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 903 - 910
  • [5] Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease
    Park, Joo-Hyun
    Lee, Jessie
    Yu, Su-Yeon
    Jung, Jin-Hyung
    Han, Kyungdo
    Kim, Do-Hoon
    Rhee, Jinnie
    BMC GERIATRICS, 2020, 20 (01)
  • [6] Association between proton pump inhibitor use and risk of fracture: A population-based case-control study
    Kim, Jong Joo
    Jang, Eun Jin
    Park, Jiwon
    Sohn, Hyun Soon
    PLOS ONE, 2020, 15 (07):
  • [7] Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis
    Chen, C. -H.
    Lin, C. -L.
    Kao, C. -H.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (06) : 2117 - 2126
  • [8] Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study
    Wang, C-Y.
    Fu, S-H.
    Wang, C-L.
    Chen, P-J.
    Wu, F-L. L.
    Hsiao, F-Y.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 (01) : 57 - 63
  • [9] Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: A nationwide population-based and multicenter cohort study using a common data model
    Park, Da Hee
    Seo, Seung In
    Lee, Kyung Joo
    Kim, Jinseob
    Kim, Yerim
    Seo, Won-Woo
    Lee, Hyung Seok
    Shin, Woon Geon
    Yoo, Jong Jin
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (08) : 1534 - 1543
  • [10] Use of proton pump inhibitors and risk of iron deficiency: a population-based case-control study
    Tran-Duy, A.
    Connell, N. J.
    Vanmolkot, F. H.
    Souverein, P. C.
    de Wit, N. J.
    Stehouwer, C. D. A.
    Hoes, A. W.
    de Vries, F.
    de Boer, A.
    JOURNAL OF INTERNAL MEDICINE, 2019, 285 (02) : 205 - 214